Novartis Pharmaceuticals Business Systems Analyst Salaries in New York
The average Novartis Pharmaceuticals Business Systems Analyst in New York earns an estimated $99,869 annually, which includes an estimated base salary of $89,180 with a $10,689 bonus. Novartis Pharmaceuticals' Business Systems Analyst compensation is $16,399 more than the US average for a Business Systems Analyst. Business Systems Analyst salaries at Novartis Pharmaceuticals in New York can range from $47,650 - $195,000.
In New York, The Operations Department at Novartis Pharmaceuticals earns $654 more on average than the Finance Department.
Last updated 2 years ago.
- $89,180
- avg. base
- $10,689
- avg. bonus
Business Systems Analyst Salaries at Novartis Pharmaceuticals
In New York, Business Systems Analysts earn $2,516 more than Business Analysts, and $5,922 less than Operations Managers.
Compensation at Novartis Pharmaceuticals by Department
In New York, The Operations Department averages $654 more than the Finance Department, and $5,107 less than the Marketing Department
Business Systems Analyst Compensation by Gender (All Companies)
The average female Business Systems Analyst at companies similar size to Novartis Pharmaceuticals reported making $89,933, while the average male Business Systems Analyst at similar sized companies reported making $93,781.
Business Systems Analyst Compensation by Ethnicity (All Companies)
The average Native American Business Systems Analyst at companies similar size to Novartis Pharmaceuticals reported making $115,000, while the average African American/Black Business Systems Analyst at similar sized companies reported making $75,705.
How Business Systems Analysts at Novartis Pharmaceuticals Rate Their Compensation
The majority of Business Systems Analysts at Novartis Pharmaceuticals believe they're compensated fairly. 100% of Business Systems Analysts at Novartis Pharmaceuticals say they receive annual bonuses, and the vast majority (79%) are satisfied with their benefits. See more compensation ratings at Novartis Pharmaceuticals
